On July 14 , 2022 , Shenzhen Aixindawei Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Aixindawei" or "the Company") reported that the first subject of the Phase II clinical trial of its independently developed and world-first product AST – 3424 for the treatment of hepatocellular carcinoma has been successfully enrolled at Guangdong Qifu Hospital and successfully completed the first dose (Press release, Ascentawits Pharmaceuticals, JUL 14, 2022, View Source [SID1234650306]). This trial ( CTR20191399 ) is a development label, single-arm, non-randomized Phase II clinical study designed to evaluate the efficacy and safety of AST-3424 in the treatment of patients with hepatocellular carcinoma. The trial will be conducted in 7 research centers across the country. Dr. Duan Jianxin, founder and chairman of Aixindawei, said: "Liver cancer is a common cancer in China. According to the 2020 Global Cancer Report, in 2020 , the proportion of new liver cancer patients in China accounted for nearly 50% of the new liver cancer patients in the world . In recent years, with the addition of treatment options such as immunotherapy, the overall survival of patients with advanced liver cancer has been significantly improved. However, how to further improve the efficacy and reduce toxic and side effects, accurately select suitable patients, and reduce the payment pressure of patients are still the direction of future efforts. The company’s independently developed small molecule targeted conjugate drug AST-3424 is expected to bring different treatment options for liver cancer patients. "
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
About AST-3424
AST-3424 is an innovative small molecule conjugate drug. After entering tumor cells overexpressing AKR1C3 enzyme, it can be highly selectively activated by AKR1C3 enzyme to release effective drugs and achieve precise killing of tumor cells. In the Phase I clinical study of solid tumors, AST-3424 showed good safety and tolerability. With the further development of subsequent clinical research, the company will combine the companion diagnostic kit developed independently to achieve accurate screening and treatment of the target population.